| Variablea |
Overall (n=215) |
SSC group (n=87) |
iSSC group (n=128) |
p |
| Demographics |
|
|
|
|
| Age (years) |
69.4 (± 12.7) |
69.0 (± 13.1) |
69.6 (± 12.4) |
0.73 |
| Male sex |
64.7% (139) |
70.1% (61) |
60.9% (78) |
0.17 |
| Weight (kg) |
84.3 (± 16.1) |
85.8 (± 17.3) |
83.4 (± 15.2) |
0.29 |
| Body mass index (kg/m2) |
29.5 (± 5.2) |
29.9 (± 5.6) |
29.3 (± 4.9) |
0.40 |
| Obesity (BMI>30) |
77.2% (166) |
77.0% (67) |
77.3% (99) |
0.96 |
| Metabolic variables |
|
| Diabetes Type 1 |
3.7% (8) |
4.6% (4) |
3.1% (4) |
0.56 |
| Diabetes Type 2 |
96.3% (207) |
95.4% (83) |
96.9% (124) |
0.58 |
| Time since diabetes diagnosis (months) |
12.4 (± 10.3) |
14.9 (± 11.2) |
11.1 (± 9.6) |
0.03 |
| Admission HbA1c (%) |
7.8 (± 1.4) |
7.9 (± 1.6) |
7.8 (± 1.3) |
0.66 |
| Initial blood glucose level (mmol/L) |
11.5 (± 4.8) |
12.0 (± 5.9) |
11.1 (± 4) |
0.22 |
| Dyslipidaemia |
50.7% (109) |
42.5% (37) |
56.3% (72) |
0.04 |
| Comorbidities and smoking status |
|
|
|
|
| Hypertension |
75.8% (163) |
78.2% (68) |
74.2% (95) |
0.57 |
| Chronic renal failure |
34.4% (74) |
31.0% (27) |
36.7% (47) |
0.39 |
| Malignancy |
16.3% (35) |
16.1% (14) |
16.4% (21) |
0.95 |
| Dementia |
8.8% (19) |
12.67% (11) |
6.3% (8) |
0.11 |
| Current or former smoker |
55.8% (120) |
58.6% (15) |
53.9% (69) |
0.42 |
| Medication on admission |
|
|
|
|
| Metformin |
45.6% (98) |
44.8% (39) |
46.1% (59) |
0.91 |
| Sulfonylurea |
32.6% (70) |
31.0% (27) |
33.6% (43) |
0.76 |
| Other oral anti-diabetic agents |
16.7% (36) |
14.9% (13) |
18.0% (23) |
0.19 |
| Any insulin |
30.7% (66) |
29.9% (26) |
31.3% (40) |
0.83 |
| Total daily insulin dose, U |
33.1 (± 19.4) |
29.1 (± 19.3) |
35.4 (± 19.3) |
0.25 |
| Steroid treatment |
16.7% (36) |
17.2% (15) |
16.4% (21) |
0.86 |
| Hospital variables |
|
|
|
|
Cause of hospitalisation
LRTI
Acute cardiac condition |
47.4% (102)
52.6% (113) |
50.6% (44)
49.4% (43) |
45.3% (58)
54.7% (70) |
0.49 |
BMI: Body-Mass Index; LRTI: Lower Respiratory Tract Infection; SD: Standard Deviation